Bone Biologics Co. (NASDAQ:BBLG) Sees Significant Increase in Short Interest

Bone Biologics Co. (NASDAQ:BBLG) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 55,100 shares, a growth of 9.8% from the December 31st total of 50,200 shares. Currently, 10.3% of the shares of the company are sold short. Based on an average trading volume of 224,100 shares, the days-to-cover ratio is presently 0.2 days.

Bone Biologics Stock Up 14.0 %

NASDAQ BBLG traded up $0.16 during trading hours on Monday, hitting $1.27. The company had a trading volume of 505,931 shares, compared to its average volume of 241,993. Bone Biologics has a 52 week low of $0.80 and a 52 week high of $4.74. The firm has a 50 day simple moving average of $1.07 and a 200 day simple moving average of $1.42.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.